BioMelbourne Network Progressing BioIndustry

10th - 12th July - Hack Aging with HealthXL
HealthXL is bringing together a fantastic mix of innovation, IT and design ... More

BioMelbourne Network

The BioMelbourne Network is a membership based, industry forum representing business leaders in biotechnology, medical technology and innovation industries in Victoria. The power of our network resides with our members, who are some of the largest life sciences companies in Australia. Our mission is to support, connect and enable growth of our sector, through networking and professional development events that provide access to industry intelligence and promote peer-to-peer knowledge exchange.

Circadian receives IND approval from FDA to initiate clinical trial of OPT - 302 for wet AMD patients

15 June 2015.  ASX and Media ReleaseCircadian receives IND approval from FDA to initiate clinical trial of OPT-302 for wet AMD patients Melbourne, Australia – Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) through its wholly owned subsidiary Opthea Pty Ltd is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to... read more…

Tax Competitiveness for Advanced Manufacturing the key to commercialising Australian R&D

15 June 2015 A more competitive corporate tax rate would enable Australia to attract valuable investment in advanced manufacturing and in turn convert its world leading R&D into fully-fledged industries located in Australia, according to CSL Limited, Australia’s largest biotechnology company. Australia has a skilled workforce, quality education and strong research base. These are the pillars ... read more…

Antisense Therapeutics announces license deal with Sweden based Cortendo

12 June 2015.  Cortendo AB (publ) [ticker: CORT on NOTC-A], a biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and Antisense Therapeutics Limited [ticker: ANP on ASX] today announced that the companies have entered into an exclusive license agreement that provides Cortendo with development and commercialization rights to Antisense Therapeutics’ ATL1103 for ... read more…

Commonwealth provides $10.6 million investment in projects for accelerating commercialisation

11 June 2015.  Eighteen Australian companies will receive grants to propel their innovative ideas from the drawing board into the marketplace under the Australian Government’s Accelerating Commercialisation programme.Industry and Science Minister Ian Macfarlane said the first round of $10.6 million in funding under the Accelerating Commercialisation element of the Australian Government’s $484.2... read more…

Design + Industry - "We’re Good Design Award Winners!"

10 June 2015.  The D+I team enjoyed another great night celebrating their design achievements at the 2015 Good Design Awards. With two prestigious Design Awards and three Design Selections they are thrilled with their winning results.Their work with Siemens Healthcare Diagnostics and Universal Biosensors for the Xprecia Stride™ Coagulation System won a Good Design Award in the Medical and Scien... read more…

LBT Begins Key U.S. Trial of APAS Technology

9 June 2015.  Australian medical technology company LBT Innovations Limited (ASX: LBT) has commenced the United States phase of the clinical trial programme for its pioneering culture-plate intelligent image analysis technology, APAS® (Automated Plate Assessment System). The trial now underway at TriCore Reference Laboratories in New Mexico is in support of LBT’s 510(k) de novo submission to t... read more…

Global Kinetics Corporation Closes $14.8 million Capital Raising

2 June 2015.  Australian health technology company Global Kinetics Corporation has successfully raised $14.8 million to rapidly progress the company’s global commercialisation strategy for its lead Parkinson’s KinetiGraph™ (PKG™) mobile health technology. Foundation investor Brandon Capital Partners has contributed further capital in the funding round. New investors include institutional inve... read more…

Aussie Hearing Invention Wins Coveted Awards

2 June 2015.  On May 29 2015, Good Design Australia presented Melbourne hearing device company Blamey Saunders hears with the inaugural Social Innovation award, in recognition of the IHearYou® system's role in creating a better society by removing barriers to quality hearing aids; barriers like cost, stigma and distance to service providers. Judges called it: “An innovation that not only has a ... read more…

Gordagen Commences Clinical Trial Program for Evidence-Based Nutraceuticals

28 May 2015.  Gordagen Pharmaceuticals, a privately-held company commercializing evidence-based nutraceuticals and pharmaceuticals, today announced that it has received approval from Bellberry Limited, Australia’s National Human Research Ethics Committee (HREC) to commence its Phase I study of natural tocotrienols.   The Single Ascending Dose (“SAD”) study will assess the safety, tolerability a... read more…

New Awards Recognise Women in Leadership in Biotech, Medtech and Healthcare Technology

22 May 2015.  Australian women do comparatively well in biotechnology, medtech and health care technology – with 11.1% of companies in the sector in the ASX 200 having female executive key management personnel and 11.9% in the ASX 500.However, in recognition that these figures need to improve and to honor outstanding women in the sector, The BioMelbourne Network will, this Friday, announce its ... read more…

dorsaVi Secures London Underground and VINCI Construction as its First UK Occupational Health and Safety Customers

21 May 2015.  Medical device company dorsaVi Ltd (ASX: DVL) today announced the signing of its first two UK-based occupational health and safety (OHS) customers: London Underground and VINCI Construction UK Ltd. The agreements with the two industry leaders represent a major milestone for the Australian company who formally introduced its innovative OHS technology, ViSafe™, into the UK market in... read more…

Starpharma - Spare Lab/Office Space

21 May 2015.  Starpharma has some surplus lab and office space at their new premises in Abbotsford. Good lab space is certainly hard to find so hopefully it would be of benefit to all of you. Read the brochure below for more details: read more…

Gordagen Wins High Court of Malaysia Judgement for Breach of Confidentiality

20 May 2015.  Gordagen Pharmaceuticals Pty. Ltd., a private Australian company commercialising evidence-based dietary supplements and pharmaceuticals, today announced that the High Court of Malaysia has issued a judgement against Ms. Nurul Athirah binti Sufi (Ms. Athirah), a former employee of the Company. Ms. Athirah was represented to Gordagen in January 2014, as a chartered accountant with a... read more…

INV102 (Oral Nadolol) Data Presented to American Thoracic Society Meeting in Denver, Colorado

19 May 2015.  Australian respiratory technology company Invion Limited (ASX: IVX) has presented data from a trial of lead compound INV102 (oral nadolol) to international medical experts at a prestigious US pulmonary conference.Trial investigators have shown delegates at the American Thoracic Society (ATS) meeting that an ongoing Phase 2 study of Invion’s INV102 as an aid to smoking cessation ha... read more…

Your invitation to the Industry Growth Centre Consultations for the Medical Technologies and Pharmaceuticals Sector

18 May 2015.  Dr Bronwyn Evans, Chair of the Medical Technologies and Pharmaceuticals Industry Growth Centre would like to invite you to participate in a range of consultations designed to shape the future of the sector. Dr Evans has scheduled a range of opportunities for interested participants to share their views about how the productivity and competitiveness of the sector can be significan... read more…

Australia’s Minister for Industry and Science Declares Trajan is “Leading the Way” in World Class, Australian-Based Advanced Manufacturing

15 May 2015.  Pioneering collaboration and world-class products meeting global standards – these were the take-home impressions of the Australian Minister for Industry and Science, Ian Macfarlane, during a special visit to Trajan Scientific and Medical (Trajan) global headquarters facilitated by Mr Michael Sukkar, Federal Member for Deakin, Victoria.Trajan exports 98 per cent of its products th... read more…

Phosphagenics: Oxymorphone Patch Program Update

14 May 2015.  Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), has completed a review of its TPM®/Oxymorphone patch development program using specialist external consultants. On the back of previously announced clinical trial results showing that the TPM®/Oxymorphone patch can deliver blood levels of oxymorphone corresponding to the therapeutic levels seen with ... read more…

Sun Biomedical Limited to Aquire Dimerix Bioscience

13 May 2015.   The Board of Sun Biomedical Ltd, an Australian biotechnology company, is pleased to announce that the Company has signed an implementation agreement to acquire 100% of Dimerix Bioscience Ltd (Dimerix), a public unlisted clinical stage drug discovery and development company, based in Melbourne. Dimerix’s lead clinical program is a Phase 2 study in patients with Chronic K... read more…

Nexvet Appoints Dr. Jurgen Horn as Chief Product Development Officer

11 May 2015.  Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, today announced it has appointed former Elanco and Novartis Animal Health executive Dr. Jürgen Horn as its new Chief Product Development Officer. Dr. Horn will commence his role at Nexvet in August 2015. Dr. Horn most recently served as Senior Director of Global Innovation Strategy at Elanco, one of the wor... read more…

OPT-302 Data Presented at Two Major Ophthalmology Conferences

7 May 2015.  Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) reports that  Dr Kameran Lashkari of Schepens Eye Research Institute/Massachusetts Eye & Ear at Harvard Medical School presented preclinical data overnight at the annual ARVO  conference in Denver demonstrating efficacy with Circadian’s targeted therapy OPT-302 (VGX-300). The data demonstrates OPT-302 reduced blood vessel growth... read more…